BRMS1 like transcriptional repressorGenealiases: BRMS1 · p40
Q-omics provides the consensus-scored BRMS1L profile across patient tissues and cancer cell-line models. BRMS1L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, BRMS1L is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, BRMS1L protein abundance shows 29,545 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, HNSC, and GBM as cancer lineages where BRMS1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BRMS1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BRMS1L survival associations across molecular data types. BRMS1L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BRMS1L RNA expression–survival associations across cancer types. High BRMS1L expression shows unfavorable associations in BLCA, STAD, LIHC and BRCA, but favorable associations in KIRC and LGG. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for BRMS1L RNA expression.
This table summarizes BRMS1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for BRMS1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BRMS1L shows lower tumor expression in THCA, KIRC, KICH and KIRP and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher BRMS1L RNA expression in tumor versus normal tissue (log2 FC = +1.064, t-test p < 0.001).
This table shows molecular features associated with BRMS1L in patient tissues and cancer cell lines. In patient samples, BRMS1L shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, BRMS1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
